Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$223.78
-3.36-1.48%
At close: -
$223.78
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Bio-Rad Laboratories Analyst Ratings and Price Targets | NYSE:BIO | Benzinga
Bio-Rad Laboratories Inc has a consensus price target of $387.43 based on the ratings of 7 analysts. The high is $550 issued by Credit Suisse on August 4, 2023. The low is $270 issued by Wells Fargo on April 17, 2025. The 3 most-recent analyst ratings were released by UBS, Citigroup, and RBC Capital on May 2, 2025, respectively. With an average price target of $350.67 between UBS, Citigroup, and RBC Capital, there's an implied 56.70% upside for Bio-Rad Laboratories Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Citigroup
RBC Capital
Wells Fargo
Jefferies
1calculated from analyst ratings
Analyst Ratings for Bio-Rad Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/02/2025 | Buy Now | 38.53% | UBS | Dan Leonard54% | $355 → $310 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | 56.4% | Citigroup | Patrick Donnelly80% | $400 → $350 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | 75.17% | RBC Capital | Conor McNamara36% | $409 → $392 | Maintains | Outperform | Get Alert |
| 04/17/2025 | Buy Now | 20.65% | Wells Fargo | Brandon Couillard69% | $320 → $270 | Maintains | Equal-Weight | Get Alert |
| 02/12/2025 | Buy Now | 54.17% | Wells Fargo | Brandon Couillard69% | $360 → $345 | Maintains | Equal-Weight | Get Alert |
| 01/14/2025 | Buy Now | 114.94% | RBC Capital | Conor McNamara36% | $481 → $481 | Reiterates | Outperform → Outperform | Get Alert |
| 12/09/2024 | Buy Now | 114.94% | RBC Capital | Conor McNamara36% | $369 → $481 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 101.09% | Citigroup | Patrick Donnelly80% | $400 → $450 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 109.58% | RBC Capital | Conor McNamara36% | $446 → $469 | Maintains | Outperform | Get Alert |
| 10/01/2024 | Buy Now | 78.75% | Citigroup | Patrick Donnelly80% | $350 → $400 | Upgrade | Neutral → Buy | Get Alert |
| 08/27/2024 | Buy Now | 51.93% | Wells Fargo | Brandon Couillard69% | → $340 | Initiates | → Equal-Weight | Get Alert |
| 08/16/2024 | Buy Now | 79.19% | RBC Capital | Conor McNamara36% | $401 → $401 | Reiterates | Outperform → Outperform | Get Alert |
| 08/02/2024 | Buy Now | 79.19% | RBC Capital | Conor McNamara36% | $402 → $401 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | 56.4% | Citigroup | Patrick Donnelly80% | $300 → $350 | Maintains | Neutral | Get Alert |
| 06/03/2024 | Buy Now | 40.76% | Jefferies | — | $440 → $315 | Assumes | Buy → Hold | Get Alert |
| 05/08/2024 | Buy Now | 72.04% | UBS | Dan Leonard54% | $420 → $385 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 63.11% | Citigroup | Patrick Donnelly80% | $400 → $365 | Downgrade | Buy → Neutral | Get Alert |
| 02/16/2024 | Buy Now | 87.68% | UBS | Dan Leonard54% | $395 → $420 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 114.5% | RBC Capital | Conor McNamara36% | $484 → $480 | Maintains | Outperform | Get Alert |
| 12/07/2023 | Buy Now | 76.51% | UBS | Dan Leonard54% | → $395 | Initiates | → Buy | Get Alert |
| 08/07/2023 | Buy Now | 134.61% | Wells Fargo | Dan Leonard54% | $550 → $525 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 134.16% | RBC Capital | Conor McNamara36% | $522 → $524 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 145.78% | Credit Suisse | Dan Leonard54% | $580 → $550 | Maintains | Outperform | Get Alert |
| 06/16/2023 | Buy Now | 145.78% | Wells Fargo | Dan Leonard54% | → $550 | Initiates | → Overweight | Get Alert |
| 05/08/2023 | Buy Now | 134.61% | Citigroup | Patrick Donnelly80% | $550 → $525 | Maintains | Buy | Get Alert |
| 05/08/2023 | Buy Now | 137.29% | RBC Capital | Conor McNamara36% | $582 → $531 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 159.18% | Credit Suisse | Dan Leonard54% | $680 → $580 | Maintains | Outperform | Get Alert |
| 02/17/2023 | Buy Now | 158.74% | RBC Capital | Conor McNamara36% | $571 → $579 | Maintains | Outperform | Get Alert |
| 02/17/2023 | Buy Now | 203.87% | Credit Suisse | Dan Leonard54% | $640 → $680 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 152.48% | RBC Capital | Conor McNamara36% | → $565 | Initiates | → Outperform | Get Alert |
| 10/28/2022 | Buy Now | 186% | Credit Suisse | Dan Leonard54% | $715 → $640 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | 219.51% | Credit Suisse | Dan Leonard54% | → $715 | Initiates | → Outperform | Get Alert |
| 07/08/2022 | Buy Now | 212.81% | Citigroup | Patrick Donnelly80% | $750 → $700 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Bio-Rad Laboratories (BIO) stock?
The latest price target for Bio-Rad Laboratories (NYSE:BIO) was reported by UBS on May 2, 2025. The analyst firm set a price target for $310.00 expecting BIO to rise to within 12 months (a possible 38.53% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Rad Laboratories (BIO)?
The latest analyst rating for Bio-Rad Laboratories (NYSE:BIO) was provided by UBS, and Bio-Rad Laboratories maintained their buy rating.
When was the last upgrade for Bio-Rad Laboratories (BIO)?
The last upgrade for Bio-Rad Laboratories Inc happened on October 1, 2024 when Citigroup raised their price target to $400. Citigroup previously had a neutral for Bio-Rad Laboratories Inc.
When was the last downgrade for Bio-Rad Laboratories (BIO)?
The last downgrade for Bio-Rad Laboratories Inc happened on April 3, 2024 when Citigroup changed their price target from $400 to $365 for Bio-Rad Laboratories Inc.
When is the next analyst rating going to be posted or updated for Bio-Rad Laboratories (BIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on May 2, 2025 so you should expect the next rating to be made available sometime around May 2, 2026.
Is the Analyst Rating Bio-Rad Laboratories (BIO) correct?
While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a maintained with a price target of $355.00 to $310.00. The current price Bio-Rad Laboratories (BIO) is trading at is $223.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
